Research findings, pricing news, and vendor analysis across the peptide market.
Showing 1 to 9 of 9
Retatrutide is often discussed around 12 mg, but the trials reported meaningful dose-response data across the range. Here is what the data actually showed.
Read more →The current evidence does not show a broad human cancer-risk increase from GLP-1 drugs, and some studies suggest lower risk for obesity-related cancers. This explainer separates thyroid-label warnings, pancreatic-cancer fears, observational signals, and what the data cannot prove.
Read more →Losing 40, 70, or 100 pounds on a GLP-1 does not automatically make your brain update how your body looks. The research on body image, obesity treatment, and quality of life suggests this disconnect is real, common, and worth planning for.
Read more →New studies show that people who lose weight with GLP-1 medications can be judged more harshly than people who lose weight through diet and exercise. Here is what the stigma research means for disclosure, care-seeking, and how we talk about obesity treatment.
Read more →Hormonal shifts after 40 make weight loss harder. GLP-1 medications can help — but the research on women specifically tells a different story than the headlines.
Read more →PCOS affects 1 in 10 women and is driven by insulin resistance. GLP-1 medications target that root cause — and the early research is promising.
Read more →GLP-1s work without strict dieting — but the research shows that adding protein and resistance training dramatically improves results and prevents muscle loss.
Read more →New research from the Technical University of Munich and Harvard Medical School reveals that semaglutide and tirzepatide don't just promote weight loss — they appear to fundamentally reshape the body's metabolic and inflammatory pathways in ways researchers didn't fully anticipate.
Read more →New research from the University of Eastern Finland has found that semaglutide (Ozempic/Wegovy) is associated with significantly reduced rates of depression, anxiety, and substance use disorders — adding to a growing body of evidence that GLP-1 drugs do far more than cause weight loss.
Read more →STOP PIECING IT TOGETHER
We wrote the shortcut: five books, 45 compounds, every claim graded by the strength of the real evidence. No hype, no gatekeeping, and free updates for life whenever the market shifts. Most readers say it replaces months of forum digging.
